Agalsidase beta

FABRAZYME ® is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: FABRAZYME ® is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in labeling:

Hypersensitivity Reactions Including Anaphylaxis
Infusion-Associated Reactions

Who should not take it

None.

Storing it

Refrigerate vials of FABRAZYME at 2°C to 8°C (36°F to 46°F). Do not use FABRAZYME after the expiration date on the vial.

This product contains no preservatives. Reconstituted and diluted solutions of FABRAZYME should be used immediately. If immediate use is not possible, the reconstituted and diluted solution may be stored for up to 24 hours at 2°C to 8°C (36°F to 46°F).

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Agalsidase beta; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/agalsidase-beta
APA 7th: sofidex. (2026, August 2). Agalsidase beta. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/agalsidase-beta
AMA 11th: Agalsidase beta. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/agalsidase-beta

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.